Physician profile
David P Prange
NPI 1053352559
$4,461.92
in general payments reported to CMS, 2019-2025
21 companies · $625 in 2025
The $625 reported for 2025 was more than what 82% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $983 · 2020: $362 · 2021: $638 · 2022: $701 · 2023: $539 · 2024: $614 · 2025: $625.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,714 · Entertainment: $63.59.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,714.39 |
| Entertainment | $63.59 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bausch & Lomb Americas INC. | $1,069.50 | 2022-2025 | Infuse, Biotrue, Xiidra |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $614.07 | 2019-2021 | |
| Alcon Vision LLC | $611.30 | 2019-2025 | Total30, Precision 1, Precision7 |
| Sun Pharmaceutical Industries INC. | $342.25 | 2019-2022 | |
| Allergan, INC. | $318.00 | 2019-2022 | |
| Johnson & Johnson Vision Care, INC. | $301.82 | 2020-2025 | Acuvue |
| Abbvie INC. | $223.67 | 2023-2024 | |
| Novartis Pharmaceuticals Corporation | $149.48 | 2021-2022 | |
| Kala Pharmaceuticals, INC. | $124.43 | 2019 | |
| Abb Con-Cise Optical Group LLC | $116.38 | 2019-2023 | Spectacle Lenses, Contact Lens |
| Sight Sciences, INC. | $109.84 | 2022 | |
| Dompe US, INC. | $92.78 | 2021 | |
| Rxsight INC | $88.96 | 2024 | Rxsight Light Delivery Device (Ldd), Rxsight Contact Lens, Rxsight Injector Handpiece |
| Coopervision INC. | $70.93 | 2019 | |
| Optos, INC. | $63.59 | 2025 | Oct Ophthalmoscope, Panoramic Ophthalmoscope, Nfc-700 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lombart Brothers, INC. | $39.17 | 2021-2023 | Opd-III |
| Aerie Pharmaceuticals, INC. | $36.79 | 2020-2021 | |
| Johnson & Johnson Surgical Vision, INC. | $30.42 | 2023 | Tecnis Iol |
| Shire North American Group INC | $21.87 | 2019 | |
| Carl Zeiss Meditec Ag | $19.40 | 2020 | |
| Lkc Technologies, INC. | $17.27 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Prange listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.